Epirubicin Market Size - Global Analysis Report 2022 - 2028
The epirubicin market is projected to reach US$ 243.99 million by 2028 from US$ 191.66 million in 2021; it is expected to register a CAGR of 3.60% from 2022 to 2028.
Epirubicin is an anthracycline medicine with the first clinical trial published in 1980. The drug was designed to be favored over doxorubicin because of better efficacity and quality. It is used for chemotherapy purposes for the treatment of various cancers. The drug is prescribed alone or in combination for the primary use against breast cancer, ovarian cancer, liver cancer, bladder cancer, and others. The product works by slowing or stopping the growth of cancer cells in the body. Combination therapies include fluorouracil, epirubicin hydrochloride, and cyclophosphamide (FEC), in which the product is given along with fluorouracil and cyclophosphamide. Adjuvant therapy of epirubicin seems to be less toxic compared to monotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere. In August 2007, the product lost its patent and became generic. The product shows the limited scope in cancer treatment due to its side effects. The common side effect was the heart, bone marrow, and blood.
Epirubicin (EPI) was successfully incorporated into a solid-liquid nanoparticle formulation to produce a stable inhalable nebulized suspension for treating lung cancer.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epirubicin Market: Strategic Insights
Market Size Value in US$ 191.66 Million in 2021 Market Size Value by US$ 243.99 Million by 2028 Growth rate CAGR of 3.60% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Epirubicin Market: Strategic Insights
| Market Size Value in | US$ 191.66 Million in 2021 |
| Market Size Value by | US$ 243.99 Million by 2028 |
| Growth rate | CAGR of 3.60% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2021 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
The epirubicin market is segmented based on dosage, application, distribution channel, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends and market dynamics and the competitive analysis of the globally leading market players.
Market Insights
Rising Prevalence of Cancer
Epirubicin is an anticancer drug that falls under the category of anthracyclines and is used to treat breast cancer, stomach cancers, etc. It reduces the risk of relapse by attacking any remaining tumor cells after surgery or radiation therapy has removed most of them.
According to the American Cancer Society, the global burden of cancer is estimated to have risen to 19.3 thousand new cases in 2021 and 10.0 thousand deaths in 2020. As per the National Cancer Institute (US), an increase in the incidence and prevalence of cancer has a significant impact on society globally. According to stats by the institute, in the US, nearly 1.8 thousand people were diagnosed with cancer, and about 606,520 people developed the disease in 2020. According to the International Agency for Research on Cancer, in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases globally. Moreover, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence rate associated with cancer is expected to impact market growth significantly. According to the Centers for Disease Control and Prevention (CDC), each year in the US, about 24,500 men and 10,000 women get liver cancer, and about 18,600 men and 9,000 women die from the disease. The percentage of Americans who get liver cancer has been rising for several decades. Liver cancer is more common in other parts of the world than in the US. Hence, the rising prevalence of cancer cases is driving the epirubicin market.
The healthcare industry in the Middle East & Africa region is still developing; hence, they faced the biggest challenge due to the COVID-19 pandemic. Health authorities were worried that attempting to fight COVID-19 would indirectly contribute to an increase in deaths of ill patients, including cancer patients. The death pool of ill patients in low-cost regions was expected to increase because healthcare professionals limited their patient appointments as many hospitals had limited resources and staff.
However, the launch of COVID vaccination programs in the year 2021, in several countries controlled the situation. These efforts to control the spread will ultimately recover and restore the situations post-pandemic.
Examples of development that have promoted the growth of the epirubicin market are listed below:
- In April 2018, Hikma Pharmaceuticals PLC (Hikma, Group) announced that its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. (West-Ward), had launched Epirubicin Hydrochloride Injection, USP in 50mg/25mL and 200mg/100mL vials, the generic equivalent to Ellence. West-Ward’s Epirubicin Hydrochloride Injection, USP is a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Epirubicin Market - Application Insights
Based on application, the epirubicin market is segmented into breast cancer, liver cancer, bladder cancer, and other cancer. The breast cancer segment held the largest share of the market in 2021. The breast cancer segment is anticipated to register the highest CAGR in the market during the forecast period and the same segment is anticipated to register the highest CAGR during the forecast period. In the 1970s, epirubicin was launched as a drug to treat metastatic breast cancer, and at present, it is among the most active single agents treating breast cancer. Medicine can be used at an early stage of breast cancer to reduce the chances of breast cancer reoccurrence. It is widely used as adjuvant therapy for those who have had surgery and lymph nodes. Hence, in most cases, the medicine is usually prescribed with other medicines. In some instances, it can be used as a substitute for doxorubicin (Adriamycin) as it may cause less heart damage than doxorubicin. The medicine is injected into a vein and is often given once every three weeks or twice every 28 days for 6 cycles. The drug is made available in the market by Pfizer, Inc., and Sandoz (a Novartis AG Division), among others. There has been constant development in cancer therapeutics; hence, various companies are launching products in the market. For instance, in April 2018, Hikma Pharmaceuticals PLC launched Epirubicin Hydrochloride Injection, USP, in variants such as 50mg/25mL and 200mg/100mL vials. The product is the generic version and is equivalent to Ellence. Thus, product availability and product launches in the market are likely to enhance the market's growth during the forecast period.
Epirubicin Market - Dosage Insights
Based on dosage, the global epirubicin market is segmented into 10mg/vial, 50mg/vial, 100mg/vial, and 200mg/vial. The 50mg/vial segment held the largest share of the market in 2021; however, the 100mg/vial segment is anticipated to register the highest CAGR during the forecast period. Epirubicin 50 mg injection is an anticancer agent which is used as an adjuvant drug to treat breast cancer. It is vesicant and should be injected into veins under the supervision of qualified physicians. The effect of 10 mg epirubicin lasts for an average of 3 to 4 days. Market players operating in the epirubicin market are offering epirubicin in different dosages. For instance, Pfizer is offering epirubicin hydrochloride in 10 mg and 50 mg dosages.
Epirubicin Market - Distribution Channel Insights
Based on distribution channel, the global epirubicin market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2021. The same segment is anticipated to register the highest CAGR of 4.0% in the market during the forecast period. Hospital pharmacies are an integral aspect of patient care at a healthcare facility. Hospital pharmacy is the field that works to consistently uphold and enhance patient pharmaceutical care and medication management to the highest standards possible in a hospital setting. The hospital pharmacy is one of the primary areas in hospitals where pharmaceuticals are purchased, stored, compounded, dispensed, manufactured, tested, packaged, and distributed. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. The selection, prescription, procurement, delivery, administration, and review of pharmaceuticals are among the objectives that aim to improve patient outcomes.
Epirubicin Market Report Scope
Epirubicin Market – by Region
By geography, the epirubicin market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Epirubicin Market - Company Profiles
The epirubicin market majorly consists of players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharmaceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Dosage, Application, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSCAM, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The global epirubicin market on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and the South & Central America. North America held the largest market share for epirubicin in 2021. The United States held the largest market in North America for epirubicin, and the market is expected to grow due to rising prevalence of cancer and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the epirubicin market.
Based on dosage, the global epirubicin market is segmented into 10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial. The 50mg/Vial segment held the largest share of the market in 2021, however, 100mg/Vial segment is anticipated to register the highest CAGR in the market during the forecast period.
The epirubicin market majorly consists of the players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharamceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.
The elevated risk of adverse effects due to epirubicin is hampering the market's growth.
Factors such as rising prevalence of cancer and increasing awareness regarding cancer are propelling the market growth.
Epirubicin HCl is a class of drugs termed anthracyclines and is primarily used to treat breast cancers after surgical resection. Anthracyclines are an antibiotic isolated from the gram-positive bacteria Streptomyces. They are commonly used as chemotherapy agents and exert their antineoplastic effects by targeting the replication of DNA. Epirubicin HCl is often preferred over anthracycline doxorubicin as it has been shown to have fewer side effects. Epirubicin HCl became FDA-approved as adjuvant therapy for treating axillary node-positive breast cancers following resection under the trade name Ellence in 1999. It is currently manufactured through large-scale semi-synthetic methods using daunorubicin as starting material for its preparation.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Epirubicin Market – By Dosage
1.3.2 Global Epirubicin Market – By Application
1.3.3 Global Epirubicin Market – By Distribution Channel
1.3.4 Global Epirubicin Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epirubicin Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Epirubicin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer
5.1.2 Increasing Awareness Regarding Cancer
5.2 Market Restraints
5.2.1 Elevated Risk of Adverse Effects due to Epirubicin
5.3 Market Opportunities
5.3.1 Rising FDA Approvals for Cancer Drugs
5.4 Future Trends
5.4.1 Increase in Number of Cancer Research Programs
5.5 Impact Analysis
6. Epirubicin Market– Global Analysis
6.1 Global Epirubicin Market Revenue Forecasts and Analysis
6.2 Global Epirubicin Market, By Geography - Forecasts And Analysis
6.3 Global Epirubicin Market – Market Potential Analysis, By Region
6.4 Company Analysis
6.4.1 Market Positioning of Key Players
6.4.2 Comparative Company Analysis
6.5 Performance of Key Players
6.5.1 Pfizer, Inc.
6.5.2 Teva Pharmaceutical Industries Ltd.
7. Epirubicin Market Analysis – By Dosage
7.1 Overview
7.2 Global Epirubicin Market, by Dosage, 2022 & 2028 (%)
7.3mg/Vial
7.3.1 Overview
7.3.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.4mg/Vial
7.4.1 Overview
7.4.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.5mg/Vial
7.5.1 Overview
7.5.2mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
7.6mg/Vial
7.6.1 Overview
7.6.2 Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
8. Epirubicin Market Analysis and Forecast to 2028 – Application
8.1 Overview
8.2 Global Epirubicin Market, by Application, 2022 & 2028 (%)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.4 Liver Cancer
8.4.1 Overview
8.4.2 Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.5 Bladder Cancer
8.5.1 Overview
8.5.2 Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
8.6 Others
8.6.1 Overview
8.6.2 Other Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
9. Epirubicin Market Analysis and Forecast to 2028 – Distribution Channel
9.1 Overview
9.2 Global Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
10. Global Epirubicin Market – Geographic Analysis
10.1 North America: Epirubicin Market
10.1.1 Overview
10.1.2 North America: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.3 North America: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.4 North America: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.5 North America: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.6 North America: Epirubicin Market, by Country, 2022 & 2028 (%)
10.1.6.1 US: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.1.1 Overview
10.1.6.1.2 US: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.1.3 US: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.6.1.4 US: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.6.1.5 US: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.6.2 Canada: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.2.1 Overview
10.1.6.2.2 Canada: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.2.3 Canada: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.6.2.4 Canada: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.6.2.5 Canada: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.1.6.3 Mexico: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.3.1 Overview
10.1.6.3.2 Mexico: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.1.6.3.3 Mexico: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.1.6.3.4 Mexico: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.1.6.3.5 Mexico: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2 Europe: Epirubicin Market
10.2.1 Overview
10.2.2 Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.3 Europe: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.4 Europe: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.5 Europe: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2.6 Europe: Epirubicin Market, by Country, 2022 & 2028 (%)
10.2.6.1 Germany: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.1.1 Overview
10.2.6.1.2 Germany: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.1.3 Germany: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.6.1.4 Germany: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.6.1.5 Germany: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2.6.2 UK: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.2.1 Overview
10.2.6.2.2 UK: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.2.3 UK: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.6.2.4 UK: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.6.2.5 UK: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2.6.3 France: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.3.1 Overview
10.2.6.3.2 France: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.3.3 France: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.6.3.4 France: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.6.3.5 France: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2.6.4 Italy: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.4.1 Overview
10.2.6.4.2 Italy: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.4.3 Italy: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.6.4.4 Italy: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.6.4.5 Italy: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2.6.5 Spain: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.5.1 Overview
10.2.6.5.2 Spain: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.5.3 Spain: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.6.5.4 Spain: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.6.5.5 Spain: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.2.6.6 Rest of Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.6.1 Overview
10.2.6.6.2 Rest of Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.2.6.6.3 Rest of Europe: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.2.6.6.4 Rest of Europe: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.2.6.6.5 Rest of Europe: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3 Asia Pacific: Epirubicin Market
10.3.1 Overview
10.3.2 Asia Pacific: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.3 Asia Pacific: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.4 Asia Pacific: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.5 Asia Pacific: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3.6 Asia Pacific: Epirubicin Market, by Country, 2022 & 2028 (%)
10.3.6.1 China Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
10.3.6.1.1 Overview
10.3.6.1.2 China: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.6.1.3 China: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.6.1.4 China: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.6.1.5 China: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3.6.2 Japan Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
10.3.6.2.1 Overview
10.3.6.2.2 Japan: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.6.2.3 Japan: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.6.2.4 Japan: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.6.2.5 Japan: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3.6.3 India Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
10.3.6.3.1 Overview
10.3.6.3.2 India: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.6.3.3 India: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.6.3.4 India: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.6.3.5 India: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3.6.4 South Korea Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
10.3.6.4.1 Overview
10.3.6.4.2 South Korea: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.6.4.3 South Korea: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.6.4.4 South Korea: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.6.4.5 South Korea: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3.6.5 Australia Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
10.3.6.5.1 Overview
10.3.6.5.2 Australia: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.6.5.3 Australia: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.6.5.4 Australia: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.6.5.5 Australia: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.3.6.6 Rest of Asia Pacific Epirubicin Market Revenue and Forecasts to 2028 (US$ Thousand)
10.3.6.6.1 Overview
10.3.6.6.2 Rest of Asia Pacific: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
10.3.6.6.3 Rest of Asia Pacific: Epirubicin Market, by Dosage, 2019–2028 (US$ Thousand)
10.3.6.6.4 Rest of Asia Pacific: Epirubicin Market, by Application, 2019–2028 (US$ Thousand)
10.3.6.6.5 Rest of Asia Pacific: Epirubicin Market, by Distribution Channel, 2019–2028 (US$ Thousand)
10.4 Middle East & Africa Epirubicin Market Revenue and Forecasts To 2028
10.4.1 Overview
10.4.2 Middle East & Africa: Epirubicin Market - Revenue and Forecast to 2028 (US$ Thousand)
10.4.3 Middle East & Africa: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.4.4 Middle East & Africa Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
10.4.5 Middle East & Africa Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
10.4.6 Middle East & Africa: Epirubicin Market, by Country, 2022 & 2028 (%)
10.4.6.1 Saudi Arabia: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.1.1 Saudi Arabia: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.1.2 Saudi Arabia: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.4.6.1.3 Saudi Arabia Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.1.4 Saudi Arabia Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.2 UAE: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.2.1 UAE: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.2.2 UAE: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.4.6.2.3 UAE Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.2.4 UAE Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.3 South Africa: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.3.1 South Africa: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.3.2 South Africa: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.4.6.3.3 South Africa Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.3.4 South Africa Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.4 Rest of Middle East & Africa: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.4.1 Rest of Middle East & Africa: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.4.6.4.2 Rest of Middle East & Africa: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.4.6.4.3 Rest of Middle East & Africa: Epirubicin Market, by Application, 2019–2028 (USD Thousand)
10.4.6.4.4 Rest of Middle East & Africa: Epirubicin Market, by Distribution Channel, 2019–2028 (USD Thousand)
10.5 South and Central America Epirubicin Market Revenue and Forecasts To 2028
10.5.1 Overview
10.5.2 South and Central America: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.3 South and Central America: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.5.4 South and Central America: Epirubicin Market, by Application, 2019–2028 (USD Thousand)
10.5.5 South and Central America: Epirubicin Market, by Distribution Channel, 2019–2028 (USD Thousand)
10.5.6 South and Central America: Epirubicin Market, by Country, 2022 & 2028 (%)
10.5.6.1 Brazil: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.6.1.1 Overview
10.5.6.1.2 Brazil: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.6.1.3 Brazil: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.5.6.1.4 Brazil: Epirubicin Market, by Application, 2019–2028 (USD Thousand)
10.5.6.1.5 Brazil: Epirubicin Market, by Distribution Channel, 2019–2028 (USD Thousand)
10.5.6.2 Argentina: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.6.2.1 Overview
10.5.6.2.2 Argentina: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.6.2.3 Argentina: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.5.6.2.4 Argentina: Epirubicin Market, by Application, 2019–2028 (USD Thousand)
10.5.6.2.5 Argentina: Epirubicin Market, by Distribution Channel, 2019–2028 (USD Thousand)
10.5.6.3 Rest of South and Central America: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South and Central America: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
10.5.6.3.3 Rest of South and Central America: Epirubicin Market, by Dosage, 2019–2028 (USD Thousand)
10.5.6.3.4 Rest of South and Central America: Epirubicin Market, by Application, 2019–2028 (USD Thousand)
10.5.6.3.5 Rest of South and Central America: Epirubicin Market, by Distribution Channel, 2019–2028 (USD Thousand)
11. Impact of COVID-19 Pandemic on Global Epirubicin Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic
12. Epirubicin Market–Industry Landscape
12.1 Overview
12.2 Growth Strategies
12.2.1 Overview
13. Company Profiles
13.1 Pfizer Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Salius Pharma Pvt Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Areva Pharmaceuticals
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 MYLAN N.V.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Hikma Pharmaceuticals PLC
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Fresenius Kabi AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 MIRACALUS PHARMA PVT. LTD.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 2. North America: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 3. North America Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 4. US Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 5. US Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 6. US Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 7. Canada Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 8. Canada Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 9. Canada Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 10. Mexico Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 11. Mexico Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 12. Mexico Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 13. Europe Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 14. Europe: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 15. Europe Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 16. Incidence, Mortality and Prevalence by cancer site, 2018, Germany
Table 17. Germany Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 18. Germany: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 19. Germany Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 20. UK Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 21. UK: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 22. UK Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 23. Incidence, Mortality and Prevalence by cancer site, 2018, France
Table 24. France Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 25. France: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 26. France Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 27. Incidence, Mortality and Prevalence by cancer site, 2018, Italy
Table 28. Italy Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 29. Italy: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 30. Italy Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 31. Incidence, Mortality and Prevalence by cancer site, 2018, Spain
Table 32. Spain Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 33. Spain: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 34. Spain Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 35. Rest of Europe Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 36. Rest of Europe: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 37. Rest of Europe Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 38. Asia Pacific Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 39. Asia Pacific: Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 40. Asia Pacific Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 41. China Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 42. China Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 43. China Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 44. Japan Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 45. Japan Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 46. Japan Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 47. India Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 48. India Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 49. India Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 50. South Korea Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 51. South Korea Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 52. South Korea Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 53. Incidence, Mortality and Prevalence by cancer site, Australia, 2018
Table 54. Australia Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 55. Australia Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 56. Australia Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 57. Rest of Asia Pacific Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (US$ Thousand)
Table 58. Rest of Asia Pacific Epirubicin Market, by Application – Revenue and Forecast to 2028 (US$ Thousand)
Table 59. Rest of Asia Pacific Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Thousand)
Table 60. Middle East & Africa Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 61. Middle East & Africa Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 62. Middle East & Africa Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 63. Saudi Arabia Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 64. Saudi Arabia Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 65. Saudi Arabia Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 66. UAE Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 67. UAE Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 68. UAE Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 69. South Africa Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 70. South Africa Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 71. South Africa Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 72. Rest of Middle East & Africa Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 73. Rest of Middle East & Africa Epirubicin Market, by Application– Revenue and Forecast to 2028 (USD Thousand)
Table 74. Rest of Middle East & Africa Epirubicin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Thousand)
Table 75. South and Central America: Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 76. South and Central America: Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 77. South and Central America: Epirubicin Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Thousand)
Table 78. Brazil: Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 79. Brazil: Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 80. Brazil: Epirubicin Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Thousand)
Table 81. Argentina: Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 82. Argentina: Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 83. Argentina: Epirubicin Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Thousand)
Table 84. Rest of South and Central America: Epirubicin Market, by Dosage – Revenue and Forecast to 2028 (USD Thousand)
Table 85. Rest of South and Central America: Epirubicin Market, by Application – Revenue and Forecast to 2028 (USD Thousand)
Table 86. Rest of South and Central America: Epirubicin Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Thousand)
Table 87. Recent Growth Strategies in the Epirubicin Market
Table 88. Glossary of Terms, Epirubicin Market
LIST OF FIGURES
Figure 1. Epirubicin Market Segmentation
Figure 2. Epirubicin Market, By Region
Figure 3. Global Epirubicin Market Overview
Figure 4.mg/Vial Segment Held Largest Share of Dosage Segment in Epirubicin Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Epirubicin Market, by Geography (US$ Thousand)
Figure 7. Global Epirubicin Market- Leading Country Markets (US$ Thousand)
Figure 8. North America: PEST Analysis
Figure 9. Europe: PEST Analysis
Figure 10. Asia Pacific: PEST Analysis
Figure 11. Middle East And Africa: PEST Analysis
Figure 12. South And Central America: PEST Analysis
Figure 13. Experts Opinion
Figure 14. Impact Analysis of Drivers and Restraints on Epirubicin Market
Figure 15. Global Epirubicin Market – Revenue Forecasts and Analysis – 2020- 2028
Figure 16. Global Epirubicin Market – By Geography Forecasts and Analysis – 2022- 2028
Figure 17. Global Epirubicin Market – Market Potential Analysis, By Region
Figure 18. Market Positioning Of Key Players In Global Epirubicin Market
Figure 19. Global Epirubicin Market – Comparative Company Analysis
Figure 20. Global Epirubicin Market, by Dosage, 2022 & 2028 (%)
Figure 21.mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 22.mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 23.mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 24. Mg/Vial Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 25. Global Epirubicin Market, by Application, 2022 & 2028 (%)
Figure 26. Breast Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 27. Liver Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 28. Bladder Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 29. Other Cancer Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 30. Global Epirubicin Market, by Distribution Channel, 2022 & 2028 (%)
Figure 31. Hospital Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 32. Retail Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 33. Online Pharmacies Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 34. North America: Epirubicin Market, by Key Country – Revenue (2022) (US$ Thousand)
Figure 35. North America Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 36. North America: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 37. US: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 38. Canada: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 39. Mexico: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 40. Europe: Epirubicin Market, by Key Country – Revenue (2022) (US$ Thousand)
Figure 41. Europe Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 42. Europe: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 43. Germany: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 44. UK: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 45. France: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 46. Italy: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 47. Spain: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 48. Rest of Europe: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 49. Asia Pacific: Epirubicin Market, by Key Country – Revenue (2022) (US$ Thousand)
Figure 50. Asia Pacific Epirubicin Market Revenue and Forecast to 2028 (US$ Thousand)
Figure 51. Asia Pacific: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 52. China: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 53. Japan: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 54. India: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 55. South Korea: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 56. Australia: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 57. Rest of Asia Pacific: Epirubicin Market – Revenue and Forecast to 2028 (US$ Thousand)
Figure 58. Middle East & Africa: Epirubicin Market, by Key Country – Revenue (2022) (US$ Thousand)
Figure 59. Middle East & Africa Epirubicin Market Revenue and Forecast to 2028 (USD Thousand)
Figure 60. Middle East & Africa: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 61. Saudi Arabia: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 62. UAE: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 63. South Africa: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 64. Rest of Middle East & Africa: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 65. South and Central America: Epirubicin Market, by Key Country – Revenue (2022) (USD Thousand)
Figure 66. South and Central America Epirubicin Market Revenue and Forecast to 2028 (USD Thousand)
Figure 67. South and Central America: Epirubicin Market, by Country, 2022 & 2028 (%)
Figure 68. Brazil: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 69. Argentina: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 70. Rest of South and Central America: Epirubicin Market – Revenue and Forecast to 2028 (USD Thousand)
Figure 71. Impact Of COVID-19 Pandemic in North American Country Markets
Figure 72. Impact of COVID-19 Pandemic in European Country Markets
Figure 73. Impact of COVID-19 Pandemic in Asia Pacific Countries
Figure 74. Impact Of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 75. Impact of COVID-19 Pandemic in South and Central American Countries
The List of Companies - Epirubicin Market
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Salius Pharma Pvt Ltd
- Areva Pharmaceuticals Mylan N. V.
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Miracalus Pharma Pvt. Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For